Altered cisplatin pharmacokinetics during nonalcoholic steatohepatitis contributes to reduced nephrotoxicity.

Acta Pharm Sin B · 2021 · PMC8727892 · PMID 35024313

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

approached significanceP = 0.06so close (0.05 < p ≤ 0.1)

Interestingly, a slight 10% reduction in liver mass approached significance ( P = 0.06) in CDDP-treated healthy ( Fig. 1 ), but not NASH rats, relative to naïve rats.

also in 8,237 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.